Selumetinib Fails to Improve Outcomes With Dacarbazine in Uveal Melanoma

The combination of selumetinib with dacarbazine did not offer improved survival outcomes over placebo/dacarbazine in patients with metastatic uveal melanoma.

Source: CancerNetwork - March 20, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Melanoma News Source Type: news